Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
Endometrial adenocarcinoma (EC) is the fifth most common cancer in women worldwide, standard treatment for EC includes hysterectomy, but it results in the loss of reproductive function. Thus, conservative trea...
Source: Reproductive Health - Category: OBGYN Authors: Xin Zhao, Jumin Niu, Cong Shi and Zhihui Liu Tags: Study protocol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Endometrial Cancer | Eyes | Fortamet | Hysterectomy | Metformin | Mirena | OBGYN | Reproduction Medicine | Study | Women